Form 4: Dianthus Therapeutics CAO Sells Shares After Option Exercise

Dianthus Therapeutics' Chief Accounting Officer, Edward Carr, exercised stock options and subsequently sold all acquired shares for a significant profit under a pre-arranged trading plan.

Summary

• Edward Carr, Chief Accounting Officer of Dianthus Therapeutics, Inc. (DNTH), executed a series of transactions on March 12, 2026.
• Carr exercised stock options to acquire a total of 43,682 shares of common stock.
• The exercise prices for these options ranged from $17.88 to $22.07 per share.
• Immediately following the option exercises, Carr sold all 43,682 shares of common stock.
• The shares were sold at weighted average prices ranging from $80.71 to $82.66, with individual transactions occurring at prices up to $85.53 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2025.
• Following these transactions, Carr beneficially owns 0 shares of common stock from these specific exercises and sales, but still holds significant unexercised stock options.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal. While the 10b5-1 plan indicates pre-planning, the complete sale of shares acquired through option exercises by a key financial officer suggests a preference for liquidity over increased direct equity exposure, which can be interpreted cautiously by investors.

Positives

• The Chief Accounting Officer realized substantial profits by exercising options at low prices ($17.88 $22.07) and selling shares at significantly higher prices ($80.71 $85.53).
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new negative information.

Negatives

• An insider, the Chief Accounting Officer, sold all shares acquired through option exercises, which could be interpreted as a lack of conviction in the company's near-term stock price appreciation, despite the 10b5-1 plan.
• The complete disposition of the acquired shares reduces the insider's direct equity stake in the company from these specific transactions.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider selling, even when pre-scheduled via a 10b5-1 plan, is often scrutinized by investors for potential signals about management's confidence. While the plan mitigates the immediate negative interpretation, the significant profit-taking by a key financial officer in the biotechnology sector, where long-term commitment is often valued, warrants attention.

Comparison to Industry Standards

• StockSavvy.ai observes that it is common for executives in growth-oriented industries like biotechnology to monetize vested stock options as part of their compensation strategy.
• However, the complete disposition of shares acquired through these exercises, rather than retaining a portion, might be viewed differently compared to executives who maintain a larger direct equity stake post-exercise, such as those at established pharmaceutical companies like Pfizer or Johnson & Johnson where executives often hold substantial long-term equity.

Stakeholder Impact

• Shareholders: May view the insider selling as a potential negative signal, though the 10b5-1 plan provides some context. The significant profit realized by the insider could also highlight the stock's past performance.
• Employees: No direct impact mentioned, but general sentiment around insider transactions can affect morale.

Key Dates

Recommendation

While the insider selling, even under a 10b5-1 plan, might raise some questions about management's immediate outlook, the significant profit realized by the Chief Accounting Officer from exercising options at much lower prices and selling at current market highs suggests strong past performance. Given the pre-planned nature of the sale, it's not an immediate red flag for a 'sell' recommendation, but it also doesn't provide a strong catalyst for a 'buy.' Investors should hold and monitor future company performance and additional insider activity.

Keywords

Dianthus Therapeutics, DNTH, Edward Carr, Insider Trading, Form 4, Stock Options, Rule 10b5-1, Share Sale, Chief Accounting Officer, Equity Compensation